Showing 1641-1650 of 1692 results for "".
- Remote Electric Neurostimulation Device Provides Pain Relief for Adolescents With Migrainehttps://practicalneurology.com/news/remote-electric-neurostimulation-device-provides-pain-relief-for-adolescents-with-migraine/2469464/In a study of therapeutic remote electric neuromodulation (REN) (Nerivio; Theranica, Netanya, Israel) for the acute treatment of migraine attacks in adolescents, freedom from pain was achieved by 35% of participants. In addition, 71% had pain relief at 2 hours. Pain relief and pain freedom were s
- Ghrelin Advances to a Phase 2 Trial for Concussion Treatmenthttps://practicalneurology.com/news/ghrelin-advances-to-a-phase-2-trial-for-concussion-treatment/2469406/A phase 2 clinical trial (NCT04558346) of ghrelin (OXE103; Oxeia Biopharmaceuticals, San Diego, CA) for treating concussions has been initiated. The compound being tested is a synthetic form of the end
- Diroximel Fumarate Treatment of Relapsing MS Has Improved Gastrointestinal Tolerability and Improved Quality of Lifehttps://practicalneurology.com/news/diroximel-fumarate-treatment-of-relapsing-ms-has-improved-gastrointestinal-tolerability-and-improved-quality-of-life/2469379/In EVOLVE-MS-2 (NCT03093324) trial of diroximel fumarate (Vumerity; Biogen, Cambridge, MA), recently approved for the treatment of relapsing forms of multiple sclerosis (MS), had significantly more gastrointestinal (GI) tolerability th
- FDA Approves Ofatumumab—First and Only Self-administered B-cell Therapy for Relapsing MShttps://practicalneurology.com/news/fda-approves-ofatumumab-first-and-only-self-administered-b-cell-therapy-for-relapsing-ms/2469358/The Food and Drug Administration (FDA) has approved ofatumumab (Kesimpta; Novartis) as an subcutaneous autoinjection for treatment of relapsing forms of multiple sclerosis (RS), including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive MS (
- Enrollment Begins for Phase 1b Clinical Trial of T-cell Immunotherapy for Progressive Multiple Sclerosishttps://practicalneurology.com/news/enrollment-begins-for-phase-1b-clinical-trial-of-t-cell-immunotherapy-for-progressive-multiple-sclerosis/2469303/The first participant has been enrolled in a phase 1b study of the allogeneic EBV T-cell immunotherapy (ATA188; Atara Biotherapeutics, South San Francisco, CA), for individuals with progressive forms of multiple sclerosis (MS). Participants in clinical sites across the US and Australia
- Ozanimod, a New Oral Treatment for Relapsing Multiple Sclerosis, Now Availablehttps://practicalneurology.com/news/ozanimod-a-new-oral-treatment-for-relapsing-multiple-sclerosis-now-available/2469283/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, Princeton, NJ) for treatment of relapsing forms of multiple sclerosis (MS) on March 25, 2020. Ozanimod, 0.92 mg, is a new once-daily oral medication for adults with relapsing MS. Ozanimod
- FDA Approves Apomorphine Sublingual Film for Treatment of OFF Periods in Parkinson Diseasehttps://practicalneurology.com/news/fda-aproves-apomorphine-sublingual-film-for-treatment-of-off-periods-in-parkinson-disease/2469271/The Food and Drug Administration has approved apomorphine sublingual film (Kynmobi; Sunovion, Marlborough, MA) for the acute, intermittent treatment of “off” episodes in patients with Parkinson disease (PD). This new formulation of apomorphine provides convenient administration (placi
- AAN Practice Advisory on PFO Closure After Strokehttps://practicalneurology.com/news/aan-practice-advisory-on-pfo-closure-after-stroke/2469245/The American Academy of Neurology (AAN) has released a practice advisory concluding that poststroke surgical closure of a patent foramen ovale (PFO) may be recommended for some individuals. This practice advisory is endorsed by American Heart Association/American Stroke Association, the Society f
- Medicinal Cannabis Effective for Chronic Insomnia in Clinical Trialhttps://practicalneurology.com/news/medicinal-cannabis-effective-for-chronic-insomnia-in-clinical-trial/2469225/A randomized double-blind clinical trial evaluating the efficacy of a medicinal cannabis formulation (ZTL-101; Zelira Therapeutics Ltd, Perth, Australia) for treating chronic insomnia showed that the therapy is effective and safe. Participants treated with medicinal cannabis went
- FDA Approves Ozanimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ozanimod-for-relapsing-multiple-sclerosis/2469208/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.